Valuation: Neuland Laboratories Limited

Market Cap 241B 2.5B 2.18B 2.02B 1.85B 3.51B 3.57B 24.1B 9.47B 118B 9.39B 9.18B 406B P/E 2027 *
57.4x
P/E 2028 * 41.6x
Enterprise Value 244B 2.53B 2.21B 2.05B 1.88B 3.55B 3.61B 24.39B 9.58B 119B 9.5B 9.29B 411B EV / Sales 2027 *
10.6x
EV / Sales 2028 * 8.73x
Free-Float
62.24%
Yield 2027 *
0.07%
Yield 2028 * 0.1%
1 day-1.66%
1 week-0.43%
Current month+0.77%
1 month+10.12%
3 months+25.25%
6 months+31.57%
Current year+23.59%
1 week 18,580
Extreme 18580
19,848.45
1 month 16,713.95
Extreme 16713.95
20,072
Current year 11,500
Extreme 11500
20,072
1 year 11,500
Extreme 11500
20,072
3 years 2,911.7
Extreme 2911.7
20,072
5 years 965.85
Extreme 965.85
20,072
10 years 247.3
Extreme 247.3
20,072
Manager TitleAgeSince
Chief Executive Officer 46 31/03/2026
Director of Finance/CFO - 22/11/2022
Chief Tech/Sci/R&D Officer - 28/02/2023
Director TitleAgeSince
Director/Board Member 50 31/12/2001
Chairman 82 06/01/1984
Director/Board Member 46 28/02/2007
Change 5-day change 1-year change 3-year change Capi.($)
-1.66%-0.43%+22.71%+532.71% 2.55B
+1.01%-3.76%+48.29%+161.92% 1,031B
+1.11%-3.49%+51.74%+57.19% 595B
+3.27%+0.99%+32.42%+87.18% 431B
+0.42%-1.16%+29.43%+23.64% 326B
+1.03%-0.84%+29.58%+45.15% 277B
+0.49%-5.44%+21.00%+23.80% 263B
+1.59%+4.89%-22.56%-37.35% 224B
+2.85%+1.62%+23.57%+62.17% 193B
+2.97%+0.53%+23.40%+74.96% 164B
Average +1.24%-3.29%+25.96%+103.14% 350.68B
Weighted average by Cap. +1.38%-4.30%+34.58%+80.52%

Financials

2027 *2028 *
Net sales 23.09B 240M 209M 194M 178M 336M 342M 2.31B 907M 11.27B 900M 880M 38.93B 27.8B 288M 252M 233M 214M 405M 412M 2.78B 1.09B 13.57B 1.08B 1.06B 46.87B
Net income 4.21B 43.68M 38.18M 35.31M 32.4M 61.33M 62.39M 421M 165M 2.06B 164M 160M 7.1B 5.81B 60.25M 52.66M 48.7M 44.69M 84.59M 86.06M 581M 228M 2.84B 226M 221M 9.79B
Net Debt 2.94B 30.48M 26.65M 24.64M 22.61M 42.8M 43.54M 294M 115M 1.43B 114M 112M 4.95B 1.92B 19.93M 17.42M 16.11M 14.78M 27.98M 28.46M 192M 75.47M 938M 74.84M 73.19M 3.24B
Logo Neuland Laboratories Limited
Neuland Laboratories Ltd. is a global provider of active pharmaceutical ingredients (APIs) contract development and manufacturing organization (CDMO) services. It is focused on manufacture and sale of active pharmaceutical ingredients and allied services. It supports biotechnology and pharmaceutical companies in the design, development and manufacturing of complex APIs. It has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). It develops and manufactures non-exclusive APIs both Prime APIs comprising large volume, mature molecules, and specialty APIs comprising lower volume, complex molecules with less competition. It develops small molecules and peptides for clinical trials and beyond. It provides an end-to-end continuum of customized services from early-stage drug development (Pre-IND) through to commercial manufacturing of complex APIs, including process development, process optimization, analytical testing, and regulatory support.
Employees
2,183
Date Price Change Volume
16/07/26 18,773.60 -1.66% 943
15/07/26 ₹19,089.60 +0.48% 625
14/07/26 ₹18,997.85 -0.01% 514
13/07/26 ₹18,999.05 -2.65% 1,908
10/07/26 ₹19,516.65 -0.01% 1,586
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
18,773.60INR
Average target price
21,222.00INR
Spread / Average Target
+13.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NEULANDLAB Stock